Header Logo

Connection

Yaping Chu to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Yaping Chu has written about Parkinson Disease.
Yaping Chu
Connection Strength
4.193
Parkinson Disease
  1. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.468
  2. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.449
  3. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.396
  4. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.369
  5. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.322
  6. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.277
  7. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.264
  8. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.247
  9. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.191
  10. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.175
  11. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.146
  12. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.139
  13. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.110
  14. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.088
  15. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.074
  16. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.068
  17. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.058
  18. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.056
  19. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.049
  20. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.042
  21. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.040
  22. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.039
  23. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.037
  24. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.034
  25. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
    View in: PubMed
    Score: 0.027
  26. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.